Dried Blood Spot Collection Cards Market Size, Share, Forecast, 2034

(MENAFN- Straits Research) Dried Blood Spot Collection Cards Market Size and Growth Analysis

The dried blood spot collection cards market size was valued at USD 402.44 million in 2025 and is projected to grow from USD 420.75 million in 2026 to USD 608.75 million by 2034 at a CAGR of 4.73% during the forecast period 2026-2034.

The dried blood spot (DBS) collection cards market is witnessing strong growth driven by the rising adoption of decentralized diagnostic testing and microsampling technologies in infectious disease screening, therapeutic drug monitoring, and newborn screening programs. Increasing demand for low-volume, non-invasive sample collection methods is accelerating the use of DBS cards in remote patient monitoring and large-scale epidemiological studies in regions with limited cold-chain infrastructure. The market is further benefiting from expanding applications in bioanalytical research, where these cards reduce sample transportation costs and improve analyte stability for long-duration storage. Technological innovations such as chemically treated filter papers, volumetric absorptive microsampling integration, and compatibility with LC-MS/MS workflows enhance analytical precision and laboratory efficiency.

Key Takeaways

North America accounted for the largest dried blood spot collection cards market shareof 35.06% in 2025. The Asia Pacific is expected to be the fastest-growing region in the dried blood spot collection cards market during the forecast period, registering a CAGR of 7.89%. Based on card type, the FTA segment is expected to register a CAGR of 5.34% during the forecast period. Based on application, the forensic application segment is expected to grow at a CAGR of 5.13% during the forecast period. Based on end use, hospitals & clinics accounted for a share of 73.52% in 2025. The US dried blood spot collection cards market sizewas valued at USD 126.98 million in 2025 and is projected to reach USD 132.98 million in 2026.

Emerging Trends in Dried Blood Spot Collection Cards Market

Adoption of Hematocrit-compensated DBS Cards for Quantitative Bioanalysis

Growing adoption of hematocrit-independent sampling technologies for improved analytical precision in quantitative diagnostics is a major dried blood spot collection cards market trend. Conventional DBS methods produced inconsistent analyte concentrations due to differences in blood viscosity and spot spreading patterns. Companies are addressing this challenge through volumetric microsampling and patterned card technologies that ensure uniform blood collection volumes. For instance, solutions developed by Capitainer and Neoteryx are increasingly utilized in therapeutic drug monitoring and pharmacokinetic research. These advancements support regulatory compliance in pharmaceutical and clinical bioanalysis applications worldwide.

Expansion of DBS Cards in Decentralized Viral Load and Genomic Surveillance Programs

Dried blood spot collection cards are increasingly utilized in decentralized viral load monitoring and genomic surveillance initiatives for HIV, hepatitis, and emerging infectious diseases. Public health agencies are deploying DBS sampling in rural and low-resource settings because samples remain stable without ultra-cold storage during transportation. Advanced DBS cards are now optimized for RNA and DNA preservation, enabling accurate molecular diagnostics and next-generation sequencing workflows. Governments and global health organizations are expanding DBS-based screening networks to strengthen epidemiological tracking and support population-scale infectious disease monitoring programs efficiently.

Market Summary

Market Metric	Details & Data (2025-2034)
2025 Market Valuation	USD 402.44 Million
Estimated 2026 Value	USD 420.75 Million
Projected 2034 Value	USD 608.75 Million
CAGR (2026-2034)	4.73%
Study Period	2022-2034
Dominant Region	North America
Fastest Growing Region	Asia Pacific
Key Market Players	QIAGEN, PerkinElmer, Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation

Download Free Sample Report to Get Detailed Insights.

Dried Blood Spot Collection Cards Market Dynamics Market Drivers

Rising Demand for Newborn Screening Programs and Expansion of Decentralized Clinical Trials Drives Market

The expansion of national newborn screening programs is significantly increasing blood spot collection cards market demand worldwide. DBS cards are extensively used for detecting inherited metabolic disorders, congenital hypothyroidism, and cystic fibrosis using minimal neonatal blood samples. Their ability to maintain sample stability during long-distance transportation supports centralized laboratory testing efficiency. For example, the US Recommended Uniform Screening Panel (RUSP) widely relies on DBS-based neonatal screening protocols. Governments are increasingly investing in tandem mass spectrometry-integrated DBS workflows to strengthen early disease detection and preventive pediatric healthcare programs.

The growing adoption of decentralized clinical trials is driving dried blood spot collection cards market demand in pharmaceutical bioanalysis and remote patient monitoring. Drug developers increasingly utilize DBS sampling to support home-based participation in oncology, immunology, and rare disease studies without frequent hospital visits. Compared to conventional venous sampling, DBS methods significantly reduce sample transportation and storage costs while improving patient retention in multi-site trials. Pharmaceutical companies are integrating DBS workflows with LC-MS/MS platforms for pharmacokinetic studies, therapeutic drug monitoring, and biomarker analysis.

Market Restraints

Variability in Hematocrit Levels and Shortage of Skilled Personnel for DBS Sample Interpretation Restrain Market

Variability in hematocrit level is a significant dried blood spot collection cards market restraint, as differences in blood viscosity and red blood cell concentration can affect sample absorption and analyte distribution on filter paper. These variations often create inconsistencies in quantitative test results, particularly in pharmacokinetic studies, therapeutic drug monitoring, and neonatal diagnostics. Uneven blood spreading may reduce extraction accuracy and analytical reproducibility during laboratory processing. As a result, clinical laboratories and pharmaceutical companies face challenges in assay standardization, regulatory compliance, and validation of DBS-based bioanalytical testing methods.

The dried blood spot collection cards market faces limitations due to the shortage of professionals skilled in DBS sample handling, extraction, and analytical interpretation. Accurate DBS testing requires expertise in microsampling techniques, contamination control, and matrix variability correction during quantitative analysis. Many clinical laboratories in developing regions lack trained personnel capable of validating DBS workflows for pharmacokinetic studies and molecular diagnostics. This skill gap increases the likelihood of analytical inconsistencies and delays assay standardization, limiting wider adoption of DBS technologies in pharmaceutical and clinical laboratory applications globally.

Market Opportunities

Expansion of At-home Therapeutic Drug Monitoring Programs and Increasing Utilization of DBS Cards in Forensics Offer Lucrative Growth Opportunities

The growing adoption of at-home therapeutic drug monitoring programs is creating significant opportunities for the dried blood spot collection cards market growth. Healthcare providers are increasingly utilizing DBS sampling for remote monitoring of immunosuppressants, anti-epileptic drugs, and biologics without requiring hospital-based venous collection. This approach improves patient convenience while reducing laboratory logistics costs. Pharmaceutical companies and specialty diagnostic laboratories are developing DBS-compatible home collection kits integrated with telehealth platforms, enabling medication monitoring and personalized treatment optimization across chronic disease management programs.

The growing adoption of dried blood spot collection cards in forensic toxicology and anti-doping analysis is creating significant opportunities for dried blood spot collection cards market players. Forensic laboratories are increasingly using DBS sampling for narcotics detection, alcohol biomarker testing, and postmortem toxicology due to its minimal sample requirement and easier transportation. DBS cards also improve sample stability for controlled substance analysis during long-term storage. Law enforcement agencies and sports regulatory organizations are expanding DBS-based screening programs because they simplify remote sample collection while supporting accurate LC-MS/MS-based forensic and toxicological investigations.

Regional Analysis North America: Market Leadership through Expanding Newborn Screening Programs and Strong Integration of DBS Workflows

The North America dried blood spot collection cards market accounted for a share of 35.06% among all regions in 2025 due to expanding federally supported newborn screening programs, rising adoption of decentralized clinical trial models across the US, and increasing utilization of DBS-based toxicology testing in forensic laboratories. Strong presence of advanced LC-MS/MS infrastructure, reimbursement-backed diagnostic screening frameworks, and growing pharmaceutical outsourcing for remote bioanalytical sampling further strengthen regional demand for high-precision DBS collection technologies.

The dried blood sport collection cards market in the US is growing due to increasing adoption of DBS-based pharmacokinetic sampling in FDA-regulated decentralized clinical trials, expanding CDC-supported HIV and hepatitis surveillance programs, and rising utilization of at-home microsampling kits by specialty diagnostic laboratories. Strong integration of DBS workflows with high-throughput LC-MS/MS platforms and growing forensic toxicology testing across state laboratories are further accelerating demand for advanced DBS collection technologies throughout the country.

Canada's dried blood spot collection cards market is supported by increasing deployment of DBS sampling in tuberculosis monitoring programs among northern migrant communities, growing use of microsampling in opioid exposure and harm-reduction studies, and rising adoption of DBS-based vitamin D deficiency screening in remote provinces with limited diagnostic accessibility. Canadian public health laboratories are also utilizing DBS cards for environmental exposure biomonitoring, particularly in mining and industrial regions, supporting long-term toxicology and occupational health surveillance initiatives.

Asia Pacific: Fastest Growth Driven by Expanding DBS Utilization and Growing Government Investment in Toxicology Laboratories

The Asia Pacific dried blood spot collection cards market is expected to register the fastest growth with a CAGR of 7.89% during the forecast period, driven by expanding DBS utilization in large-scale thalassemia and G6PD deficiency screening programs across Southeast Asia. Rising deployment of microsampling in rural tuberculosis surveillance initiatives and increasing government investment in decentralized infectious disease diagnostics also drive dried blood spot collection cards market growth. Rapid expansion of contract research organizations conducting multi-country clinical trials and growing adoption of cost-efficient sample transport systems are further accelerating regional market demand.

Increasing DBS utilization in national forensic toxicology laboratories for narcotics and synthetic drug detection, rising adoption of DBS-based therapeutic drug monitoring for immunosuppressants in organ transplant centers, and expanding anti-doping testing programs across professional sports institutions drive the dried blood spot collection cards market in China. Growing government investment in high-throughput toxicology laboratories is further accelerating demand for advanced DBS sampling technologies.

Singapore's dried blood spot collection cards market expansion is supported by growing DBS adoption within Biopolis-linked translational research institutes, increasing use of microsampling in cross-border infectious disease surveillance at Changi-linked public health laboratories, and rising therapeutic drug monitoring applications in Singapore's advanced transplant care centers. Expansion of government-supported precision medicine initiatives and centralized biomedical testing infrastructure is further accelerating demand for high-quality DBS collection technologies across the country.

Dried Blood Spot Collection Cards Market Segmentation Analysis By Type

In 2025, the Whatman 903 segment accounted for a share of 41.20% in the dried blood collection card market, by card type. Its FDA-recognized compatibility with newborn screening workflows, superior analyte stability for tandem mass spectrometry applications, and widespread adoption in global HIV viral load monitoring programs has maintained segment dominance.

The FTA segment is expected to grow at a CAGR of 5.34% during the forecast period, driven by rising utilization in HPV genotyping, tuberculosis molecular testing, and hereditary disease screening applications requiring stable DNA preservation. Increasing adoption of PCR-based infectious disease diagnostics and expanding use of room-temperature nucleic acid transport systems are further supporting segment growth across clinical and research laboratories.

By Application

Newborn screening (NBS) led the application segment with a share of 30.76% in 2025 due to its critical role in early genetic disorder identification, including sickle cell disease and cystic fibrosis, using DBS-based multiplex assays. Strong integration with hospital-based perinatal screening programs and automated high-throughput neonatal testing platforms enhances rapid result turnaround and population-level disease prevention strategies.

The forensic application segment is expected to have the fastest growth, registering a CAGR of 5.13% during the forecast period. DBS cards are used in cold-chain-free toxicology evidence preservation, increasing their deployment in synthetic opioid metabolite screening in law enforcement labs and expanding adoption for rapid DNA-based suspect identification in decentralized crime scene investigations.

By End Use

By end use, hospitals dominated the dried blood spot collection cards market with a share of 73.52% in 2025. This dominance is attributed to high utilization in inpatient neonatal screening protocols, routine therapeutic drug monitoring in chronic disease management, and integration with hospital-based clinical pathology laboratories for centralized sample processing. Increasing hospital adoption of DBS for infectious disease testing and rapid diagnostic workflows further strengthens dominance across end-use healthcare settings.

The diagnostics centers segment is expected to grow at a CAGR of 6.48% during the forecast period, fueled by rising demand for multiplex infectious disease screening panels, increased outsourcing of pharmacogenomic and therapeutic drug testing, and adoption of cost-efficient, high-volume sample processing workflows that reduce turnaround time and improve laboratory efficiency.

Competitive Landscape

The dried blood spot collection cards market is consolidated, with a limited number of specialized diagnostics and filtration technology providers accounting for a major share of global revenues. Companies including QIAGEN, PerkinElmer, and Cytiva Whatman maintain competitive positioning through certified filter paper technologies, newborn screening expertise, and strong distribution partnerships with clinical laboratories. Market participants are increasingly investing in volumetric microsampling systems, automation-compatible DBS workflows, and molecular diagnostics integration. Emerging innovators are also focusing on hematocrit-independent sampling technologies to strengthen precision bioanalysis and decentralized diagnostic testing capabilities globally.

List of Key and Emerging Players in Dried Blood Spot Collection Cards Market

QIAGEN PerkinElmer Hoffmann-La Roche Ltd Thermo Fisher Scientific Inc. Danaher Corporation Agilent Technologies BD Centogene N.V. Bio-Rad Laboratories, Inc. GE HealthCare Shimadzu Corporation Ahlstrom-Munksjö Cytiva

Recent Developments

In March 2026: Tasso renewed SOC 2 Type II certification for its remote blood collection and DBS testing infrastructure.

In February 2026: Tasso expanded commercialization of its Tile-T20 dried whole blood cartridge and Tasso Mini device platform for decentralized clinical trials and remote testing.

In September 2025: Tasso announced that the TS Blood Collection Kit developed through the Tasso-SNBL joint venture received certification as a controlled medical device under Japan's Pharmaceuticals and Medical Devices Act

Report Scope

Report Metric	Details
Market Size in 2025	USD 402.44 Million
Market Size in 2026	USD 420.75 Million
Market Size in 2034	USD 608.75 Million
CAGR	4.73% (2026-2034)
Base Year for Estimation	2025
Historical Data	2022-2024
Forecast Period	2026-2034
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered	By Card Type, By Application, By End Use
Geographies Covered	North America, Europe, APAC, Middle East and Africa, LATAM
Countries Covered	US, Canada, UK, Germany, France, Spain, Italy, Russia, Nordic, Benelux, China, Korea, Japan, India, Australia, Taiwan, South East Asia, UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Brazil, Mexico, Argentina, Chile, Colombia

Download Free Sample Report to Get Detailed Insights.

Dried Blood Spot Collection Cards Market Segments By Card Type

Whatman 903 Ahlstrom 226 FTA Other Card Types

By Application

Newborn Screening (NBS) Infectious Diseases Testing Therapeutic Drug Monitoring Forensic Application Other Applications

By End Use

Hospitals & Clinics Diagnostics Centers Other End Uses

By Region

North America Europe APAC Middle East and Africa LATAM

MENAFN22052026004597010906ID1111154993